Aquestive Therapeutics Inc (AQST):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Aquestive Therapeutics Inc (AQST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3035)・商品コード:DATA904C3035
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:37
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Aquestive Therapeutics Inc (Aquestive Therapeutics) is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm a drug delivery platform that delivers existing prescription products directly to the bloodstream. Its products include suboxone, rizatriptan, zuplenz, clobazam, diazepam, meloxicam, colchicine, flu vaccine, and others. Aquestive Therapeutics also provides nutraceutical products, packaging solutions, consumer products, and drug products for the treatment of nausea, opioid dependence, and vomiting. The company partners with other pharmaceutical companies for the development and commercialization of pharmaceutical products. It has its operations in New Jersey and Indiana, the US. Aquestive Therapeutics is headquartered in Warren, New Jersey, the US.

Aquestive Therapeutics Inc (AQST) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aquestive Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Monosol Acquires Buccal Film Patent From Fuisz Pharma 12
Venture Financing 13
Aquestive Therapeutics Raises USD9.1 Million in Venture Financing 13
Partnerships 14
Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 14
Midatech Enters Into Joint Venture With MonoSol Rx 16
Licensing Agreements 17
Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 17
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 18
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 19
Monosol Rx Enters Into Licensing Agreement With Vestiq Pharma For Zuplenz 20
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 21
Equity Offering 22
Aquestive Therapeutics Completes Underwriters Exercise of Over-Allotment Option of IPO of Shares of Shares for USD73.9 Million 22
Aquestive Therapeutics Inc – Key Competitors 24
Aquestive Therapeutics Inc – Key Employees 25
Aquestive Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Joint Venture 26
Recent Developments 27
Corporate Communications 27
May 02, 2018: Aquestive Therapeutics Appoints Nancy Lurker to Board of Directors 27
Apr 11, 2017: MonoSol Rx Appoints James S. Scibetta to Board of Directors 28
Jan 24, 2017: MonoSol Rx Appoints John T. Maxwell as Chief Financial Officer 29
Product News 30
01/18/2018: Aquestive Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Clobazam Oral Soluble Film to Treat Lennox-Gastaut Syndrome 30
01/06/2017: Monosol Rx Successfully Completes Dose Proportionality Study Of Diazepam Buccal Soluble Film To Treat Acute Repetitive Seizures 31
Product Approvals 32
Jan 31, 2018: Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to Treat ALS 32
Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm 33
Jan 04, 2017: MonoSol Rx Receives FDA Acceptance of Investigational New Drug Application for Riluzole Oral Soluble Film to Treat Amyotrophic Lateral Sclerosis 34
Clinical Trials 35
Jan 10, 2017: MonoSol Rx to Initiate Human Proof-of-Concept Study of Epinephrine Sublingual Soluble Film 35
Other Significant Developments 36
Nov 30, 2017: MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aquestive Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aquestive Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Monosol Acquires Buccal Film Patent From Fuisz Pharma 12
Aquestive Therapeutics Raises USD9.1 Million in Venture Financing 13
Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 14
Midatech Enters Into Joint Venture With MonoSol Rx 16
Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 17
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 18
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 19
Monosol Rx Enters Into Licensing Agreement With Vestiq Pharma For Zuplenz 20
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 21
Aquestive Therapeutics Completes Underwriters Exercise of Over-Allotment Option of IPO of Shares of Shares for USD73.9 Million 22
Aquestive Therapeutics Inc, Key Competitors 24
Aquestive Therapeutics Inc, Key Employees 25
Aquestive Therapeutics Inc, Other Locations 26
Aquestive Therapeutics Inc, Joint Venture 26

List of Figures
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aquestive Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Aquestive Therapeutics Inc (AQST):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3035)販売に関する免責事項を必ずご確認ください。
★調査レポート[Aquestive Therapeutics Inc (AQST):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆